ClinicalTrials.gg
Enrolling by invitationNCT06822101VisuallearningUpdated Sep 9, 2026

Mechanisms of Perceptual Learning

An interventional study of Visual Training in Perceptual Learning, sponsored by Brown University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Brown University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to investigate how our performance changes after our perceptual system is trained in a certain way ("perceptual learning"). In addition, we are interested in identifying and characterizing relationships between such changes and neuroimaging signals recorded from the human brain.

Read the detailed description

This is a resubmission of the competitive renewal of the ongoing R01 grant. Visual perceptual learning (VPL) is an important tool that can be used to better understand visual plasticity. The long-term goal is to comprehensively understand the mechanisms of VPL and their underlying plasticity, which may provide important information for the development of training and rehabilitation tools and programs for improving and restoring damaged, declining or degraded vision. This proposal aims to examine the roles of global processing, such as reward and arousal, in the specificity of VPL, which is one of the most important characteristics of VPL. VPL is generally characterized as specific to the trained feature and the retinal location in which the feature is presented, minimally transferring to other features or locations. The specificity of VPL may impose serious restrictions on the use of VPL in clinical applications that require generalized effects in everyday life. Early studies suggested that the specificity of VPL comes from properties of neurons in early visual areas. However, later studies indicate that the specificity is greatly influenced by global processing that does not originate in early visual areas. The current proposal aims to examine the roles of global processing such as reward and arousal in the generalizability and specificity of VPL. No research has ever been conducted to test whether and how reward and arousal each influence the generalizability/specificity of VPL. There are two types of VPL. Task-irrelevant VPL (TIVPL) refers to the learning resulting from passive exposure to a task-irrelevant feature or object, whereas task-relevant VPL (TRVPL) refers to the learning of a task-relevant feature or object through a given task. Significantly different mechanisms may underlie these two types of VPL. Thus, the abovementioned questions will be addressed for TIVPL and TRVPL in Specific Aims 1 and 2, respectively. Our preliminary results consistently suggest the following aspects: (1)Arousal plays a role in generalizing the trained feature or object to untrained features or untrained objects within the same category of the trained object, whereas reward is not involved in the generalization of VPL and rather plays a role in inducing the specificity of VPL. (2) Generalization due to arousal is not involved in reinforcement processing, which may play an important role in the specificity of VPL due to reward. The information that will be obtained from the research results is expected to be important for the development of a clinical training method, for which the generalization of VPL is crucial. We will test the following hypotheses by psychophysics. Hypothesis (H)1: Reward plays a role in increasing the specificity of TIVPL and TRVPL. H2: Arousal plays a role in increasing the generalizability of TIVPL and TRVPL. H3: H1 and H2 are valid for both VPL of a primitive feature and VPL of an object. H4: Reinforcement processing is involved in the role that reward plays in the specificity of TIVPL and TRVPL, whereas it is not involved in the role of arousal in the generalizability of TIVPL and TRVPL.

02

Conditions studied

  • Perceptual Learning

Browse trials for

Keywords

  • Behavioral
03

In context

Behavior

1,573 studies on the registry are indexed under Behavior; 313 are open to participants now.

This study's planned enrollment of 400 is above the median of 120 across 1,197 interventional studies indexed under Behavior.

Browse Behavior studies →

Lead sponsor

Brown University is the lead sponsor of 290 studies on the registry; 40 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 - 60,
  • Normal or corrected-to-normal vision

Exclusion criteria

Exclusion Criteria:

  • Eye disorders (cataracts, age related macular degeneration, diabetic retinopathy, glaucoma)
  • Drug use (psychoactive drugs, neuroleptic medications, prescription medications that might affect cognitive and motor performance)
  • Sleep disorders (sleep apnea, insomnia)
  • Magnetically or mechanically activated implants (such as cardiac pacemakers)
  • clips on blood vessels in the brain
  • intrauterine devices
  • dentures
  • pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Interventions

  • BehavioralVisual Training

    Participants are asked to detect or discriminate visual stimuli.

06

What researchers measure

Primary outcomes

  1. Behavioral measure

    Changes in rates of correct detection or discrimination in behavioral visual tasks after training are measured.

    Time frame: From enrollment to the end of treatment at 2 weeks.

07

Study locations

1 site
08

References and documents

Publications

  • Seitz AR, Kim D, Watanabe T. Rewards evoke learning of unconsciously processed visual stimuli in adult humans. Neuron. 2009 Mar 12;61(5):700-7. doi: 10.1016/j.neuron.2009.01.016. PubMed 19285467 ↗
  • Sasaki Y, Nanez JE, Watanabe T. Advances in visual perceptual learning and plasticity. Nat Rev Neurosci. 2010 Jan;11(1):53-60. doi: 10.1038/nrn2737. Epub 2009 Dec 2. PubMed 19953104 ↗
  • Watanabe T, Sasaki Y. Perceptual learning: toward a comprehensive theory. Annu Rev Psychol. 2015 Jan 3;66:197-221. doi: 10.1146/annurev-psych-010814-015214. Epub 2014 Sep 10. PubMed 25251494 ↗

Individual participant data

Plan to share: Yes — The types of data to be produced in the current project will be behavioral data and participants' demographic information will also be collected. All data will be de-identified before receipt by the repository. Programs for visual stimuli and data analyses will be produced in the project.

Supporting information: Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2028, 39 months after the start.

Of 741 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 39 months is above that.

Counting every sponsor, half of 757 studies reached it within 13 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 12, 2025
StartActual
Feb 11, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06822101
Lead sponsor
Brown University
Responsible party
Takeo Watanabe (Fred M. Seed Professor, Brown University) — Principal investigator
First posted
Feb 12, 2025
Start date
Feb 11, 2025
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion